As filed with the Securities and Exchange Commission on March 23, 2022
Registration No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
The
Securities Act of 1933
ITEOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
37-3365066 |
(State or other jurisdiction of |
|
(I.R.S. Employer |
incorporation or organization) |
|
Identification No.) |
321 Arsenal Street
Watertown, MA 02472
(339) 217-0162
(Address, including zip code and telephone number, including area code, of Registrants principal executive offices)
iTeos Therapeutics, Inc. 2020 Stock Option and Incentive Plan
(Full title of the plans)
Michel Detheux, Ph.D.
Chief Executive Officer
iTeos Therapeutics, Inc.
321 Arsenal Street
Watertown, MA 02472
(339) 217-0162
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Paul
M. Kinsella
Ropes & Gray LLP
Prudential Tower
800
Boylston Street
Boston, MA 02199-3600
(617) 951-7000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐